The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
p62 is a multi-functional protein, which induces nuclear factor-κB (NFκB) activation through multiple upstream signalling pathways, including those triggered by the epidermal growth factor (EGF) family of receptors. We hypothesised that p62 overexpression increased EGF family receptor expression and worse outcome in breast cancer would be associated. We stained a tissue microarray representing 523 breast cancers using a commercial guinea pig anti-human p62 sera and standard immunohistochemical methods to address this. Out of n = 106 tumours, 20.3% stained positively. p62 expression correlated with grade (P = 0.010) and distant metastasis (P = 0.04) and EGF receptor (EGFR) (P = 0.012), HER2 (P = 0.016), HER3 (P = 0.007) and HER4 (0.002) expressions. Though expression correlated with reduced 5-year survival (58.5 vs 73.6%), there was no association with overall disease specific survival. p62 expression may represent a marker of activation of the NFκB pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
REporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Hocking, L. J., Lucas, G. J., Daroszewska, A., Cundy, T., Nicholson, G. C., Donath, J., Walsh, J. P., Finlayson, C., Cavey, J. R., Ciani, B., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0403015 · Cited by 156
Self-citation
Cited by
Jain, A., Lamark, T., Sjøttem, E., Bowitz Larsen, K., Atesoh Awuh, J., Øvervatn, A., McMahon, M., Hayes, J. D., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118976 · Cited by 1,472
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer
Shin, D., Kim, E. H., Lee, J., & Roh, J.-L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.426 · Cited by 534
Valencia, T., Kim, J. Y., Abu-Baker, S., Moscat-Pardos, J., Ahn, C. S., Reina-Campos, M., Duran, A., Castilla, E. A., Metallo, C. M., Diaz-Meco, M. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.004 · Cited by 304
Pankiv, S., Lamark, T., Bruun, J.-A., Øvervatn, A., Bjørkøy, G., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039925 · Cited by 266
Metadata
- Authors
- Rolland, P., Madjd, Z., Durrant, L., Ellis, I. O., Layfield, R., & Spendlove, I.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2007-03
- Volume
- 14
- Issue
- 1
- Pages
- 73-80
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2101871553
- Cited by
- 115
- References
- 2
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. https://app.cochat.ai/papers/10.1677/erc.1.01312
- The paper
- Rolland, P., Madjd, Z., Durrant, L., Ellis, I. O., Layfield, R., & Spendlove, I. (2007). The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocrine-Related Cancer. https://doi.org/10.1677/erc.1.01312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.